NCT01372410 - A Randomized, Double Blind, Placebo Controlled, Incomplete Block, Crossover, Dose Ranging Study to Evaluate the Dose Response of GSK573719 Administered Once or Twice Daily Over 7 Days in Patients With Chronic Obstructive Pulmonary Disease (COPD) | Biotech Hunter

Enrollment

163

Participants

Timeline

Start Date

July 1, 2011

Primary Completion Date

October 1, 2011

Study Completion Date

October 27, 2011

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

GSK573719

125 mcg once daily

DRUG

GSK573719

62.5 mcg once daily

DRUG

GSK573719

31.25 mcg once daily

DRUG

GSK573719

15.6 mcg once daily

DRUG

GSK573719

31.25 mcg twice daily

DRUG

GSK573719

15.6 mcg twice daily

DRUG

Tiotropium

18 mcg once daily

DRUG

Placebo

once or twice daily

Trial Locations (13)

27607

GSK Investigational Site, Raleigh

28207

GSK Investigational Site, Charlotte

29118

GSK Investigational Site, Orangeburg

29303

GSK Investigational Site, Spartanburg

29340

GSK Investigational Site, Gaffney

29379

GSK Investigational Site, Union

29615

GSK Investigational Site, Greenville

29640

GSK Investigational Site, Easley

30096

GSK Investigational Site, Duluth

30342

GSK Investigational Site, Atlanta

55438

GSK Investigational Site, Edina

73103

GSK Investigational Site, Oklahoma City

92626

GSK Investigational Site, Costa Mesa